Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Fenebrutinib

Generic Name: Fenebrutinib

Drug Type: Small Molecule

Chemical Formula: C_₃₇H_₄₄N_₈O_₄

CAS Number: 1434048-34-6

Unique Ingredient Identifier: E9L2885WUL

Overview

Fenebrutinib is under investigation in clinical trial NCT03174041 (A Drug-Drug Interaction Study Between GDC-0853 and Midazolam, Itraconazole, Rosuvastatin, and Simvastatin).

Background

Fenebrutinib is under investigation in clinical trial NCT03174041 (A Drug-Drug Interaction Study Between GDC-0853 and Midazolam, Itraconazole, Rosuvastatin, and Simvastatin).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

Phase 2

Recruiting

Posted: 2025/05/11

Sponsor:Hoffmann-La Roche

ID:NCT06965413

A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy

Phase 2

Active, not recruiting

Posted: 2022/09/21

Sponsor:Hoffmann-La Roche

ID:NCT05548556

A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)

Phase 2

Active, not recruiting

Posted: 2021/11/15

Sponsor:Hoffmann-La Roche

ID:NCT05119569

A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy

Phase 2

Active, not recruiting

Posted: 2021/11/10

Sponsor:Hoffmann-La Roche

ID:NCT05115110

Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Phase 3

Active, not recruiting

Posted: 2020/10/14

Sponsor:Hoffmann-La Roche

ID:NCT04586023

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Roche's Phase III MUSETTE Trial Confirms Current OCREVUS Dose Optimal for Multiple Sclerosis

2 months ago

The Phase III MUSETTE trial found that higher doses of OCREVUS (ocrelizumab) provided no additional benefit in slowing disability progression in relapsing multiple sclerosis patients compared to the standard 600 mg dose.

Scholar Rock Submits Apitegromab BLA to FDA for Spinal Muscular Atrophy Treatment

4 months ago

Scholar Rock has submitted a Biologics License Application (BLA) to the FDA for apitegromab to treat spinal muscular atrophy (SMA).

Tolebrutinib Receives FDA Breakthrough Therapy Designation for Non-Relapsing Secondary Progressive Multiple Sclerosis

5 months ago

The FDA has granted Breakthrough Therapy designation to tolebrutinib for adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS).

Roche Reports Strong Q3 Growth Driven by Key Pharmaceuticals and Diagnostics

7 months ago

Roche's Group sales increased by 6% in the first nine months of 2024, driven by high demand for both medicines and diagnostics, with a 9% rise in Q3.

TAK-906: Peripheral D2/D3 Antagonist Under Development for Gastroparesis

8 months ago

TAK-906, developed by Altos Therapeutics and Takeda, is a peripherally-restricted D2/D3 receptor antagonist designed to treat gastroparesis.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy